Nilotinib cross-intolerance in patients with imatinib-intolerance: hematologic AEs
| . | Reason for imatinib intolerance . | |||
|---|---|---|---|---|
| Hematologic AE . | Anemia . | Neutropenia . | Thrombocytopenia . | |
| CML-CP (n = 95) | ||||
| Imatinib-intolerant* grade 3/4 AE or persistent grade 2 AE, n (%) | 31 (33) | 3 (3) | 9 (9) | 25 (26) |
| Grade 3/4 AE or persistent grade 2 AE on nilotinib, n† | 19 | 1 | 5 | 16 |
| Grade 3/4 AE on nilotinib, n‡ | 17 | 1 | 5 | 14 |
| AE that led to dose reduction on nilotinib, n | 12 | 0 | 2 | 10 |
| Discontinuation on nilotinib attributable to AE, n | 7 | 0 | 0 | 7 |
| CML-AP (n = 27) | ||||
| Imatinib-intolerant* grade 3/4 AE or persistent grade 2 AE, n (%) | 9 (33) | 1 (4) | 3 (11) | 6 (22) |
| Grade 3/4 AE or persistent grade 2 AE on nilotinib, n† | 4 | 1 | 2 | 2 |
| Grade 3/4 AE on nilotinib, n‡ | 4 | 0 | 2 | 2 |
| AE that led to dose reduction on nilotinib, n | 3 | 0 | 2 | 1 |
| Discontinuation on nilotinib attributable to AE, n | 0 | 0 | 0 | 0 |
| All patients (N = 122) | ||||
| Imatinib-intolerant* grade 3/4 AE or persistent grade 2 AE, n (%) | 40 (33) | 4 (3) | 12 (10) | 31 (25) |
| Grade 3/4 AE or persistent grade 2 AE on nilotinib, n† | 23 | 2 | 7 | 18 |
| Grade 3/4 AE on nilotinib, n‡ | 21 | 1 | 7 | 16 |
| AE that led to dose reduction on nilotinib, n | 15 | 0 | 4 | 11 |
| Discontinuation on nilotinib attributable to AE, n | 7 | 0 | 0 | 7 |
| . | Reason for imatinib intolerance . | |||
|---|---|---|---|---|
| Hematologic AE . | Anemia . | Neutropenia . | Thrombocytopenia . | |
| CML-CP (n = 95) | ||||
| Imatinib-intolerant* grade 3/4 AE or persistent grade 2 AE, n (%) | 31 (33) | 3 (3) | 9 (9) | 25 (26) |
| Grade 3/4 AE or persistent grade 2 AE on nilotinib, n† | 19 | 1 | 5 | 16 |
| Grade 3/4 AE on nilotinib, n‡ | 17 | 1 | 5 | 14 |
| AE that led to dose reduction on nilotinib, n | 12 | 0 | 2 | 10 |
| Discontinuation on nilotinib attributable to AE, n | 7 | 0 | 0 | 7 |
| CML-AP (n = 27) | ||||
| Imatinib-intolerant* grade 3/4 AE or persistent grade 2 AE, n (%) | 9 (33) | 1 (4) | 3 (11) | 6 (22) |
| Grade 3/4 AE or persistent grade 2 AE on nilotinib, n† | 4 | 1 | 2 | 2 |
| Grade 3/4 AE on nilotinib, n‡ | 4 | 0 | 2 | 2 |
| AE that led to dose reduction on nilotinib, n | 3 | 0 | 2 | 1 |
| Discontinuation on nilotinib attributable to AE, n | 0 | 0 | 0 | 0 |
| All patients (N = 122) | ||||
| Imatinib-intolerant* grade 3/4 AE or persistent grade 2 AE, n (%) | 40 (33) | 4 (3) | 12 (10) | 31 (25) |
| Grade 3/4 AE or persistent grade 2 AE on nilotinib, n† | 23 | 2 | 7 | 18 |
| Grade 3/4 AE on nilotinib, n‡ | 21 | 1 | 7 | 16 |
| AE that led to dose reduction on nilotinib, n | 15 | 0 | 4 | 11 |
| Discontinuation on nilotinib attributable to AE, n | 7 | 0 | 0 | 7 |
AE indicates adverse event; AP, accelerated phase; CML, chronic myeloid leukemia; and CP, chronic phase.
Patients with multiple reasons for imatinib intolerance are counted in each category.
Number of imatinib-intolerant patients who experienced any grade 3/4 AE or grade 2 AE that persisted for > 30 days during nilotinib therapy and was the same corresponding reason for imatinib intolerance.
Number of imatinib-intolerant patients who experienced any grade 3/4 AE during nilotinib therapy that was the same corresponding reason for imatinib intolerance.